GLPwatch

Semaglutide-Associated Gastric Pneumatosis.

ACG Case Rep J · 2024

Last updated 2026-05-29
JournalACG Case Rep J, 2024
Citations3
Relative citation ratio1.36
NIH percentile61
Molecules semaglutide

Abstract

Semaglutide, a glucagon-like peptide-1 receptor agonist, used for Type 2 diabetes mellitus and more recently for weight loss, often causes gastrointestinal adverse effects such as delayed gastric emptying and abdominal discomfort. Current literature has not described an associated case of gastric pneumatosis with semaglutide use. We report a 61-year-old man on semaglutide for 9 months with gastric pneumatosis. Symptoms resolved on discontinuation. Clinicians should be vigilant for significant gastrointestinal adverse effects, including pneumatosis with semaglutide use.

Verbatim abstract via PubMed 39734391 ↗

Related research